Advanced search
Publication Cover
Journal of Medical Economics Volume 20, 2017 - Issue 11
Submit an article Journal homepage
2,204
Views
14
CrossRef citations to date
0
Altmetric
Psychiatry

Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands

Thomas R. EinarsonLeslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0003-3865-2533
ORCID Icon,
Basil G. BerezaLeslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada; ORCID Iconhttp://orcid.org/0000-0002-8151-3961
ORCID Icon,
Fadi TedouriJanssen Janssen Pharmaceutica NV, Beerse, Belgium; ORCID Iconhttp://orcid.org/0000-0002-3257-9729
ORCID Icon,
Kristel Van ImpeJanssen-Cilag BV, Tilburg, The Netherlands; ORCID Iconhttp://orcid.org/0000-0003-1119-9871
ORCID Icon,
Tom R. DeneeJanssen-Cilag BV, Tilburg, The Netherlands; ORCID Iconhttp://orcid.org/0000-0002-0150-2091
ORCID Icon &
Pieter J. T. DriesBavo Europoort, Rotterdam, The NetherlandsORCID Iconhttp://orcid.org/0000-0002-2120-8762
ORCID Icon
Pages 1187-1199 | Received 27 Jun 2017, Accepted 24 Jul 2017, Published online: 14 Aug 2017

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Juan Antonio García-Carmona & Sofia Pappa. (2023) Cumulative Clinical Experience of the Use of Paliperidone Palmitate 3-Monthly Long-Acting Injection in the Treatment of Schizophrenia: A Critical Appraisal. Drug, Healthcare and Patient Safety 15, pages 113-123.
Read now
Alicia Lopez & Jose Rey. (2019) Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice. Neuropsychiatric Disease and Treatment 15, pages 449-456.
Read now
Junwen Zhou, Aurélie Millier, Clément François, Samuel Aballéa & Mondher Toumi. (2019) Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results. Journal of Market Access & Health Policy 7:1.
Read now
Miquel Bioque & Miquel Bernardo. (2018) The current data on the 3-month paliperidone palmitate formulation for the treatment of schizophrenia. Expert Opinion on Pharmacotherapy 19:14, pages 1623-1629.
Read now
Claudio Brasso, Silvio Bellino, Paola Bozzatello, Cristiana Montemagni & Paola Rocca. (2017) Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia. Neuropsychiatric Disease and Treatment 13, pages 2767-2779.
Read now

Articles from other publishers (9)

Rui Luo, He Lu & Hengfen Li. (2023) Cost-utility analysis of using paliperidone palmitate in schizophrenia in China. Frontiers in Pharmacology 14.
Crossref
Grace Hsin-Min WangMikael SvenssonHui ShaoScott Martin VouriHaesuk Park. (2023) Cost-effectiveness analysis of monthly, 3-monthly, and 6-monthly long-acting injectable and oral paliperidone in adults with schizophrenia. Journal of Managed Care & Specialty Pharmacy 29:8, pages 884-895.
Crossref
Saadia SediqzadahAllison PortnoyJane J. KimMatcheri KeshavanAnkur Pandya. (2022) Cost-Effectiveness of Early Intervention in Psychosis: A Modeling Study. Psychiatric Services 73:9, pages 970-977.
Crossref
Luis Gutiérrez‐Rojas, Sergio Sánchez-Alonso, Marta García Dorado & Paola M. López Rengel. (2022) Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in Spain. CNS Drugs 36:5, pages 517-527.
Crossref
Richard Dodel, Christopher Kruse, Annette Conrads-Frank & Uwe Siebert. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy 101 234 .
Luying Wang, Fenghao Shi, Xin Guan, He Xu, Jing Liu & Hongchao Li. (2021) A Systematic Review of Methods and Study Quality of Economic Evaluations for the Treatment of Schizophrenia. Frontiers in Public Health 9.
Crossref
Huajie Jin, Stewart Robinson, Wenru Shang, Evanthia Achilla, David Aceituno & Sarah Byford. (2021) Overview and Use of Tools for Selecting Modelling Techniques in Health Economic Studies. PharmacoEconomics 39:7, pages 757-770.
Crossref
Huajie Jin, Paul Tappenden, Stewart Robinson, Evanthia Achilla, James H. MacCabe, David Aceituno & Sarah Byford. (2020) A Systematic Review of Economic Models Across the Entire Schizophrenia Pathway. PharmacoEconomics 38:6, pages 537-555.
Crossref
Richard Dodel, Christopher Kruse, Annette Conrads-Frank & Uwe Siebert. 2020. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy 1 135 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.